ClinicalTrials.gg
Not yet recruitingNCT03252626Updated Apr 1, 2024

Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke

A Phase 4 interventional study of Alprostadil and Normal saline in Stroke, sponsored by The First Hospital of Jilin University. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-01.

Sponsored by The First Hospital of Jilin University · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
950
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Ischemic stroke has a variety of treatments and currently drug therapy is one of the main treatments.A number of clinical studies have proved that alprostadil (PGE1) has pharmacological effects of significant dilation of blood vessels, inhibition of plate aggregation, anti-atherosclerosis and increased cerebral blood flow.Evaluate the 90-days efficacy by comparing two groups of patients'(one with alprostadil,another with placebo) mRS.

02

Conditions studied

  • Stroke

Browse trials for

03

In context

Stroke

8,279 studies on the registry are indexed under Stroke; 2,066 are open to participants now.

This study's planned enrollment of 950 is above the median of 49 across 6,045 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

The First Hospital of Jilin University is the lead sponsor of 186 studies on the registry; 97 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ischemic stroke diagnosed by CT or MRI
  2. Age: 18-75 years
  3. Pre-stroke mRS score is 0-1
  4. within 72 hours symptoms onset
  5. 4 ≤ NIHSS \<20
  6. Patient is willing to participate voluntarily and to sign a written patient

Exclusion criteria

Exclusion Criteria:

  1. intracranial tumors, encephalitis or lesions diagnosed by CT or MRI
  2. patients with thrombolytic therapy
  3. low , blood system diseases or other bleeding tendency
  4. suspected subarachnoid hemorrhage or aortic dissection coma
  5. atrial fibrillation, myocardial infarction, heart valve disease, infective endocarditis, heart rate \<50 beats / min
  6. or AST continued to rise more than 3 times the rate\<30ml/min
  7. Dementia and mental illness
  8. Patient who is participating in other trials or has been participated in other trials in recent 3 months
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
950 participants (estimated)

Study arms

  • Active comparator
    Alprostadil

    Based on the standard medical care, 2ml of Alprostadil

    Drug: Alprostadil

  • Placebo comparator
    Normal saline

    Based on the standard medical care, 2ml of 0.9% saline as the placebo

    Drug: Normal saline

Interventions

  • Alprostadil injection USP for intravascular infusion contains 500 micrograms Alprostadil, more commonly known as prostaglandin E1. Vasodilation, inhibition of platelet aggregation are among the most notable of these effects. 2ml Alprostadil injection added into 10ml 0.9% saline.

  • DrugNormal saline

    2ml normal saline injection added into 10ml 0.9% saline.

06

What researchers measure

Primary outcomes

  1. Modified Rankin Scale at Day 90

    Time frame: day 90

Secondary outcomes

  1. Incidence of major vascular events in 30 or 90 days including ischemic stroke and hemorrhagic stroke

    Major adverse vascular events include ischemic stroke, hemorrhagic stroke, TIA, myocardial infarction and vascular-related death.

    Time frame: day 30, day 90

  2. Incidence of stroke events in 30 or 90 days including ischemic stroke and hemorrhagic stroke

    Time frame: day 30, day 90

  3. Barthel Index score

    compared the changes in activities of daily living (Barthel index) between the two groups

    Time frame: day 30, day 90

  4. EQ-5D scale

    compared the changes in EQ-5D scale

    Time frame: day 30, day 90

  5. Documentation of adverse events (AEs)

    compared the rates of adverse events

    Time frame: day 30, day 90

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2024; primary completion for Dec 2024, 8 months later.

Of 84 non-industry phase 4 interventional studies under Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 95. This study's planned 8 months is below that.

Counting every sponsor, half of 90 studies reached it within 57 months; a quarter within 29 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2017
First posted
Aug 17, 2017
StartEst.
Apr 18, 2024
Primary completionEst.
Dec 31, 2024
CompletionEst.
Jun 30, 2025
Last update
Apr 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03252626
Responsible party
Sponsor
First posted
Aug 17, 2017
Start date
Apr 18, 2024 (estimated)
Primary completion
Dec 31, 2024 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Apr 1, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alprostadil

Start the discussion